Skip to main content
Log in

Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

With standard treatment for glioblastoma (GBM) consisting of surgery followed by radiotherapy (RT) with concurrent and adjuvant temozolomide (TMZ), median survival is ~14.6 months. This is not as informative to patients who have survived for some time. Conditional probability of survival may offer more relevant survival estimates. Outcomes/conditional probability of survival and post-progression survival (PPS) estimates were retrospectively reviewed in the TMZ treatment era of 882 consecutive patients with a diagnosis of GBM from January 2004 to August 2010. Median age of entire cohort was 62 years including 62 % males. Baseline performance status (PS) was 0–1 in 67, 23 % had frontal lobe tumors, 58 % received concurrent RT/TMZ ± adjuvant TMZ. Survival (OS) was similar for those with frontal lobe tumors versus other locations (P = 0.25). OS for patients receiving standard RT/TMZ ± TMZ was 14.2 months. Age, PS, extent of surgery, therapy post-surgery had significant effects on OS. OS for entire cohort at 1, 2, 3, 4, 5 years was 43.4, 17.9, 10.4, 8.4, 7.2 % respectively. Conditional probability of survival of an additional year given survival to 1, 2, 3, 4, 5 years was 41.4, 58, 80.7, 85.7, 81.5 % respectively. Conditional probability of survival for those patients receiving concurrent RT/TMZ ± adjuvant TMZ was similar. Patients who progress >18 months after their initial treatment for GBM had significantly greater 2 and 5 year PPS as well as OS. Conditional probabilities of survival may provide more meaningful life expectancy predictions for survivors of GBM than conventional survival outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Central Brain Tumor Registry of the United States (CBTRUS) (2009) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004–2005. www.cbtrus.org/reports/reports.html. Accessed 10 Dec 2013

  2. Gurney JG, Kadan-Lottick N (2001) Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13:160–166

    Article  CAS  PubMed  Google Scholar 

  3. Walker MD, Alexander E Jr, Hunt WE et al (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49:333–343

    Article  CAS  PubMed  Google Scholar 

  4. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  CAS  PubMed  Google Scholar 

  5. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC–NCIC trial. Lancet Oncol 10:459–466

    Article  CAS  PubMed  Google Scholar 

  6. Davis FG, McCarthy BJ, Freels S, Kupelian V, Bondy ML (1999) The conditional probability of survival of patients with primary malignant brain tumors: surveillance, epidemiology, and end results (SEER) data. Cancer 85:485–491

    Article  CAS  PubMed  Google Scholar 

  7. Polley MY, Lamborn KR, Chang SM, Butowski N, Clarke JL, Prados M (2011) Conditional probability of survival in patients with newly diagnosed glioblastoma. J Clin Oncol 29:4175–4180

    Article  CAS  PubMed  Google Scholar 

  8. Johnson DR, Ma DJ, Buckner JC, Hammack JE (2012) Conditional probability of long-term survival in glioblastoma: a population-based analysis. Cancer 118:5608–5613

    Article  PubMed  Google Scholar 

  9. Lai A, Kharbanda S, Pope WB et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490

    Article  CAS  PubMed  Google Scholar 

  10. Tsao-Wei DD, Hu J, Groshen SG, Chamberlain MC (2012) Conditional survival of high-grade glioma in Los Angeles County during the year 1990–2000. J Neurooncol 110:145–152

    Article  PubMed  Google Scholar 

  11. Verhaak RG, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Malkoun N, Chargari C, Forest F et al (2012) Prolonged temozolomide for treatment of glioblastoma: preliminary clinical results and prognostic value of p53 overexpression. J Neurooncol 106:127–133

    Article  CAS  PubMed  Google Scholar 

  13. Krell D, Assoku M, Galloway M, Mullholland P, Tomlinson I, Bardella C (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS ONE 6:e19868

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. SongTao Q, Lei Y, Si G et al (2012) IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269–273

    Article  PubMed  Google Scholar 

  15. Ohgaki H, Dessen P, Jourde B et al (2004) Genetic pathways to glioblastoma: a population-based study. Cancer Res 64:6892–6899

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Princess Margaret Cancer Centre Cancer Registry. Dr. Mairéad G. McNamara is funded by the Princess Cancer Centre clinical fellowship fund. All other authors have no funding to declare.

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Warren P. Mason.

Rights and permissions

Reprints and permissions

About this article

Cite this article

McNamara, M.G., Lwin, Z., Jiang, H. et al. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era. J Neurooncol 117, 153–160 (2014). https://doi.org/10.1007/s11060-014-1368-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1368-7

Keywords

Navigation